Watch LONA. Know when insiders buy.
One email the day a filing lands. Free.
LONA
LeonaBio, Inc.
4.73
−0.21 −4.25%
USD · Nov 2, 06:41 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
61
WATCH · insiders 80, shorts 42
Insiders, 90 days
+$9.9B
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $44.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$141.5MNET CASH —52W 2.87 – 11.68SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$19.5M | −$19M | — | -0.80 | −$17M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$17.2M | −$32.9M | — | -1.73 | −$20.9M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$78.6M | −$82.9M | — | -18.90 | −$19.4M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$6.9M | −$6.6M | — | -1.68 | −$4.7M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$7.3M | −$7M | — | -1.78 | −$7M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$9.5M | −$9.1M | — | -2.34 | −$14.7M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$15.6M | −$15M | — | -3.86 | −$26M | $0 | −$26M | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$29.6M | −$28.7M | — | -7.46 | −$23M | $0 | −$23M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$28M | −$26.9M | — | -0.70 | −$22.3M | $28K | −$22.4M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$27.7M | −$26.3M | — | -0.69 | −$25.8M | $5K | −$25.8M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$29M | −$27.3M | — | -0.71 | −$26.3M | $0 | −$26.3M | Feb 27 |
| Q3 2023 · Sep 30 | — | — | — | −$35M | −$33M | — | -0.87 | −$24M | $30K | −$24M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$102.3M | −$105.6M | — | -24.70 | −$45.7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$100.9M | −$96.9M | — | -25.19 | −$97.2M | $33K | −$97.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$125.5M | −$117.7M | — | -3.09 | −$100.8M | $304K | −$101.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$104M | −$95.6M | — | -2.53 | −$72.5M | $1.1M | −$73.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$64M | −$54.9M | — | -1.49 | −$43.1M | $1.6M | −$44.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$20M | −$20M | — | -1.67 | −$24.1M | $2.3M | −$26.4M | — | — |
Every number comes from LeonaBio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.